Lakhman Sukhwinder S, Chen Xiaomin, Gonzalez-Covarrubias Vanessa, Schuetz Erin G, Blanco Javier G
Department of Pharmaceutical Sciences, the State University of New York at Buffalo, Buffalo, New York 14260-1200, USA.
Mol Pharmacol. 2007 Sep;72(3):734-43. doi: 10.1124/mol.107.035550. Epub 2007 Jun 14.
Human carbonyl reductase 1 (CBR1) metabolizes a variety of substrates, including the anticancer doxorubicin and the antipsychotic haloperidol. The transcriptional regulation of CBR1 has been largely unexplored. Therefore, we first investigated the promoter activities of progressive gene-reporter constructs encompassing up to 2.4 kilobases upstream of the translation start site of CBR1. Next, we investigated whether CBR1 mRNA levels were altered in cells incubated with prototypical receptor activators (e.g., dexamethasone and rifampicin). CBR1 mRNA levels were significantly induced (5-fold) by the ligand of the aryl hydrocarbon receptor (AHR) beta-naphthoflavone. DNA sequence analysis revealed two xenobiotic response elements ((-122)XRE and (-5783)XRE) with potential regulatory functions. CBR1 promoter constructs lacking the (-122)XRE showed diminished (9-fold) promoter activity in AHR-proficient cells incubated with beta-naphthoflavone. Fusion of (-5783)XRE to the (-2485)CBR1 reporter construct enhanced its promoter activity after incubations with beta-naphthoflavone by 5-fold. Furthermore, we tested whether the potent AHR ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induced Cbr1 expression in Ahr(+/-) and Ahr(-/-) mice. TCDD induced hepatic Cbr1 mRNA (TCDD, 2-fold) and Cbr1 protein levels (TCDD, 2-fold) in Ahr(+/-) mice compared with vehicle-injected controls. In contrast, no significant Cbr1 mRNA and Cbr1 protein induction was detected in livers from Ahr(-/-) mice treated with TCDD. These studies provide the first insights on the functional characteristics of the human CBR1 gene promoter. Our data indicate that the AHR pathway contributes to the transcriptional regulation of CBR1.
人羰基还原酶1(CBR1)可代谢多种底物,包括抗癌药阿霉素和抗精神病药氟哌啶醇。CBR1的转录调控在很大程度上尚未得到探索。因此,我们首先研究了包含CBR1翻译起始位点上游多达2.4千碱基的渐进式基因报告构建体的启动子活性。接下来,我们研究了用原型受体激活剂(如地塞米松和利福平)孵育的细胞中CBR1 mRNA水平是否发生改变。芳烃受体(AHR)的配体β-萘黄酮可显著诱导CBR1 mRNA水平(5倍)。DNA序列分析揭示了两个具有潜在调控功能的外源性反应元件((-122)XRE和(-5783)XRE)。缺乏(-122)XRE的CBR1启动子构建体在用β-萘黄酮孵育的AHR功能正常细胞中显示出减弱的(9倍)启动子活性。将(-5783)XRE与(-2485)CBR1报告构建体融合后,在用β-萘黄酮孵育后其启动子活性增强了5倍。此外,我们测试了强效AHR配体2,3,7,8-四氯二苯并对二恶英(TCDD)是否能在Ahr(+/-)和Ahr(-/-)小鼠中诱导Cbr1表达。与注射赋形剂的对照组相比,TCDD在Ahr(+/-)小鼠中诱导了肝脏Cbr1 mRNA(TCDD,2倍)和Cbr1蛋白水平(TCDD,2倍)。相比之下,在用TCDD处理的Ahr(-/-)小鼠肝脏中未检测到明显的Cbr1 mRNA和Cbr1蛋白诱导。这些研究首次揭示了人CBR1基因启动子的功能特性。我们的数据表明AHR途径有助于CBR1的转录调控。